- H.C. Wainwright has increased its price target for Alector (NASDAQ: ALEC) to $8.00 from $5.00, maintaining a Buy rating on the biotechnology stock.
- Alector is actively developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, utilizing its Alector Brain Carrier platform for targeted drug delivery.
- A significant licensing agreement with Genentech, a Roche (SIX: ROG) company, provides Alector with $100.00 million upfront and extends its financial runway until 2029.
Alector (NASDAQ: ALEC) is a biotechnology company developing innovative treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. H.C. Wainwright has raised its price target on the biotech stock to $8.00 from $5.00 and maintains a Buy rating. The shares traded at $1.86 when the analyst action was posted.
Alector’s drug development strategy focuses on getting treatments into the brain, where many neurodegenerative diseases cause damage. Its clinical pipeline includes AL137, an antibody aimed at amyloid beta in Alzheimer’s disease, and two siRNA programs targeting tau and alpha-synuclein. siRNA is a method designed to reduce the production of specific proteins.
CEO Arnon Rosenthal states that Alector is shifting its focus from immune checkpoint targets toward bispecific antibodies, enzyme-replacement therapies, and nucleic acid therapies. Its proprietary Alector Brain Carrier platform is specifically designed to carry treatments across the blood-brain barrier, a critical challenge in neurodegenerative disease treatment, which limits what can enter the brain from the bloodstream.
Alector also has a global licensing agreement with Genentech, a Roche (SIX: ROG) company, for AL050, an investigational Parkinson’s therapy. Alector receives $100.00 million upfront and could receive up to $1.17 billion in milestone payments, plus royalties on sales. As highlighted by MarketBeat, Rosenthal says this strategic agreement extends Alector’s financial runway into 2029.
At $1.86, Alector shares traded $0.01, or 0.53%, lower. Its intraday trading range was $1.83 to $1.92, while its past-year range has been $1.09 to $3.40. The $8.00 price target represents an analyst estimate and is not a guaranteed future price for the biotech stock.
